There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Several people who came into contact with a woman who died of pneumonia of unknown etiology in Russia’s Irkutsk Region have tested positive for COVID-19 and rhinovirus, the country’s sanitary watchdog said.

“Laboratory tests have confirmed two COVID-19 and two rhinovirus infection cases,” Rospotrebnadzor said, adding that no other infectious disease pathogens were detected among the contacts, according to Russia’s TASS news agency.

The development comes amid reports that the woman, a researcher at an anti-plague institute in Siberia, may have been exposed to Yersinia pestis, the bacterium that causes plague. Russian authorities have not confirmed plague as the cause of her illness or death.

What Happened in Russia?

The researcher was identified by Russian reports as 28-year-old Darya Shipilova, who worked at the Irkutsk Anti-Plague Research Institute.

Russian media initially reported that Shipilova had broken a test tube containing plague bacteria in late September, subsequently developed severe pneumonia and died.

However, Rospotrebnadzor said her diagnosis was “pneumonia of unknown etiology.” Expanded testing did not identify microorganisms associated with her professional activities.

The World Health Organization said Shipilova died of severe pneumonia overnight into October 2 and that the cause of death had not been confirmed, The CBS News Report said.

Nearly 200 people who may have had contact with her have reportedly been placed under medical observation.

Rospotrebnadzor said the sanitary and epidemiological situation in Irkutsk and Shelekhov remained stable and that special measures had been implemented following her death.

Kremlin spokesman Dmitry Peskov stressed that Rospotrebnadzor was the lead agency with expertise in the matter and urged Russians to follow information from its “highly qualified professionals”, media reports said.

Trump Offers US Help

US President Donald Trump has offered to help Russia after a laboratory worker died following an illness at an anti-plague research institute in Siberia, amid reports of a suspected pneumonic plague case.

Russian authorities, however, have said the situation is under control and have not confirmed plague.

“We’ll help,” Trump told reporters at the White House. “Everybody who has that kind of a problem, we’ll always help”.

Describing the plague as a “rough disease,” Trump said he had not spoken to Russian officials about the case but that the US would do what it could to help.

“That’s a disease we used to be able to control,” Trump said, adding that “somehow those microbes have gotten stronger and stronger, they’re like an army.”

“They called it pneumonia, and pneumonia, you know, years ago, you could treat pneumonia easier. The microbes and the germs have gotten stronger disproportionately. But we’ll help them, we’ll help them,” Trump said.

US, EU Monitor Situation

The US State Department said it was monitoring the reports with the CDC and other agencies.

CDC officials said plague is a known and treatable disease, with antibiotics particularly effective when treatment begins early.

Secretary of State Marco Rubio said the situation was “not cause for alarm” but warranted continued monitoring.

The European Commission said it was “monitoring very closely” the reports and was in contact with the European Centre for Disease Prevention and Control.

WHO Says Public Risk Is Low

The World Health Organization said testing was underway and the cause of death had not been confirmed.

The WHO said it was in contact with Russian authorities and had offered support if needed. Based on available information, it assessed the risk to the general public as low.

What Is Pneumonic Plague?

Plague is caused by Yersinia pestis, a bacterium generally found in small mammals and their fleas.

The same bacterium caused the Black Death, which swept across Europe in the 14th century and killed an estimated 25 million to 50 million people.

Plague can occur in several forms. Bubonic plague primarily affects the lymph nodes, while pneumonic plague affects the lungs and is the form most capable of spreading directly between people.

Pneumonic plague can become rapidly life-threatening without treatment but is treatable with antibiotics when diagnosed and treated promptly.

The United States is in the middle of its worst measles outbreak in more than three decades as Pennsylvania has recorded more than 1,000 cases. New York also declared a disaster emergency across the state recently as the highly contagious infection continues to spread.

Pennsylvania health department reported 1,004 measles cases as of October 5, that includes 198 hospitalisations and five deaths. Lancaster County, the hardest-hit area, has reported 391 cases alone. All five people who died in the state this year were unvaccinated, according to Reuters.

The outbreak is the worst recorded in the US since the major measles resurgence between 1989 and 1991. The CDC reported 3,887 confirmed measles cases in the country as of October 1, 2026.

Measles Has Resurfaced In The US

Measles was eliminated in the US in 2000. It means that there was no continuous spread of the virus within the country. However, elimination does not always mean that the virus has disappeared globally. Imported infections can still trigger outbreaks when they infiltrate communities where vaccination coverage is insufficient.

The measles, mumps and rubella (MMR) vaccine provides about 97% protection against measles after two doses. But protection at the community level depends on high vaccination coverage as measles is extremely contagious. The CDC says more than 95% of people in a community need to be vaccinated to maintain herd immunity.

Vaccination coverage has fallen in several parts of the country, leaving several parts of communities more vulnerable to transmission.

Also read: Measles Cases Are Rising in US—Who Should Get A Booster Shot?

New York Declares A Disaster Emergency

On Monday, New York Governor Kathy Hochul declared a statewide disaster emergency after the state recorded 108 measles cases through October 3. Among these, 92 cases were reported since July 15 across 18 counties, especially in under-immunised rural communities.

The emergency, which remains in effect till November 4, authorises other group of healthcare professionals like nurses and pharmacists who can administer MMR vaccines. The state has also increased testing and vaccination efforts in affected areas.

“No ⁠one should get seriously ill or die from a vaccine-preventable disease,” Hochul said. More than 1,000 MMR doses have already been administered in rural areas since July 15.

Also read: Pennsylvania Reports Fifth Measles-Related Death As Outbreak Continues To Spread

Who May Need a Measles Booster?

The first measles vaccine was introduced in the US in 1963, but the formulation used between 1963 and 1967 was less effective than current versions. Adults vaccinated during that period may need another dose if they have not received a later measles vaccine.

People born before 1957 are generally considered to have presumptive evidence of immunity because measles circulated widely before routine vaccination, and most people in this age group were naturally infected.

Some people may need individualized vaccination guidance rather than standard recommendations, including:

• People with uncertain vaccination status or no vaccination records
• People who received an inactivated measles vaccine between 1963 and 1967
• People with a weakened immune system
• Pregnant people

Also read: Rabies Day Exclusive: ‘We Need To Target The Source’ For A Rabies-Free India By 2030, Says Veterinary Epidemiologist

Death Toll According To CDC & Pennsylvania

The CDC has reported 13 measles deaths in the US so far in 2026. The deaths have occurred among people who were not fully vaccinated or whose vaccination status was unknown.

There is a striking discrepancy in the reported death toll. Pennsylvania health officials say five residents have died after getting infected with measles this year, but the CDC’s national tally lists only two measles-related deaths across the US.

The CDC has shifted to relying on death-certificate data reviewed by the National Center for Health Statistics, while Pennsylvania uses the state definition that considers factors including a positive measles test, symptoms and the timing of death. The CDC has said it is working with state epidemiologists on a standard definition and that its count could change after reviews.

Measles is a highly contagious viral infection that spreads through respiratory droplets and can remain in the air after an infected person leaves an area. It commonly causes high fever, cough, runny nose and a characteristic rash, but complications can get serious. These can include pneumonia, swelling of the brain and, in extreme cases, death.

Young children, pregnant women and people with weak immunity systems are more prone to develop serious complications of measles.

A new drug combination has shown promise in treating people diagnosed with diffuse large B-cell lymphoma (DLBCL), reducing the risk of progression or death by 51% compared to the current treatment alone.

The findings come from the Phase 3 EPCORE DLBCL-2 trial, which tested the addition of epcoritamab to R-CHOP, a standard chemotherapy and immunotherapy regimen used to treat DLBCL. The companies developing the drug, Genmab and AbbVie, announced the ]results on October 5.

Findings From The Lymphoma Trial

The trial evaluated newly diagnosed patients with DLBCL and other large B-cell lymphomas who had an International Prognostic Index (IPI) score of 2 to 5, indicating varying levels of disease risk.

Patients received either epcoritamab plus R-CHOP or R-CHOP alone. The combination reduced the risk of disease progression or death by 51%, with a hazard ratio of 0.49 and a p-value below 0.0001. The benefit was seen in the trial’s primary higher-risk group as well as the broader population included in the study.

The companies said this is the first Phase 3 study of a bispecific antibody combination to demonstrate a significant improvement in progression-free survival in newly diagnosed DLBCL.

Also read: World Meningitis Day: Why 1 In 3 Meningitis Deaths Occur In Children Under 5

How Does Epcoritamab Work?

Epcoritamab is a bispecific antibody that engages T-cell. Unlike chemotherapy, which directly targets rapidly dividing cells, the drug is designed to bring the body’s immune cells into closer contact with cancer cells.

It binds to CD3 on T cells and CD20 on B cells, effectively directing T cells towards CD20-positive cancer cells so they can attack them.

R-CHOP, meanwhile, combines rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone and has been a standard treatment for DLBCL for decades.

“DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a new standard of care in newly diagnosed DLBCL patients,” said Daejin Abidoye, MD, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology, AbbVie.

Also read: Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000

Hope For A New Course Of Treatment In Blood Cancer

DLBCL is the most common type of non-Hodgkin lymphoma, accounting for around 25% to 30% of non-Hodgkin lymphoma cases worldwide. Although R-CHOP has improved outcomes, some patients still experience disease progression or relapse.

The new findings suggest that bringing a bispecific antibody into treatment from the time of initial diagnosis could improve how long patients remain free from disease progression.

“As an investigator with firsthand experience in both the landmark trial that established R-CHOP as a standard of care nearly 25 years ago and EPCORE DLBCL-2, it is particularly meaningful to see the potential benefit of bispecific antibody therapy in newly diagnosed diffuse large B-cell lymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center.

But the combination is still investigational and has not been approved for newly diagnosed DLBCL. The companies said they plan to engage regulatory authorities globally based on the results.

Full trial data will also be presented at a future medical meeting, meaning detailed results, including the complete safety and survival data, are still awaited.